L. Shirmohammadi, M. Ghayour-Mobarhan, M. Saberi-Karimian, M. Iranshahi, S. Tavallaie, M. Emamian, A. Sahebkar
{"title":"Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome.","authors":"L. Shirmohammadi, M. Ghayour-Mobarhan, M. Saberi-Karimian, M. Iranshahi, S. Tavallaie, M. Emamian, A. Sahebkar","doi":"10.2174/1871529X19666190919110652","DOIUrl":null,"url":null,"abstract":"BACKGROUND/OBJECTIVE Inflammatory processes lead to increase the risk of metabolic syndrome (MetS). Cathepsin D is one of the main proinflammatory mediators. In current study, we aimed to investigate the effect of curcumin on serum cathepsin D in patients with MetS. MATERIALS AND METHODS The current study was conducted on 18-65 years old individuals with MetS according to the criteria of \"IDF\" guidelines. A total of 80 participants were randomly divided into two groups: treatment and control groups. The first group (n=40) were given 2 capsules containing 500mg of phosphatidylcholine complex of curcumin, and the other group (n=40) were given two 500mg capsules contain lactose as placebo for 6 weeks. Before (week 0) and after (week 6) the intervention, anthropometric indices and blood pressure were measured and blood samples were taken. Serum cathepsin D was measured using an abcam ELISA kit. RESULTS There were no significant differences between treatment and control groups in regard to weight, BMI, waist circumference and serum cathepsin D levels before and after the intervention. Also, there were no significant differences between pre and post-trial values of serum cathepsin D. CONCLUSION The results shows curcumin has not a significant effect on cathepsin D level in patients with MetS.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"41 6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X19666190919110652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
BACKGROUND/OBJECTIVE Inflammatory processes lead to increase the risk of metabolic syndrome (MetS). Cathepsin D is one of the main proinflammatory mediators. In current study, we aimed to investigate the effect of curcumin on serum cathepsin D in patients with MetS. MATERIALS AND METHODS The current study was conducted on 18-65 years old individuals with MetS according to the criteria of "IDF" guidelines. A total of 80 participants were randomly divided into two groups: treatment and control groups. The first group (n=40) were given 2 capsules containing 500mg of phosphatidylcholine complex of curcumin, and the other group (n=40) were given two 500mg capsules contain lactose as placebo for 6 weeks. Before (week 0) and after (week 6) the intervention, anthropometric indices and blood pressure were measured and blood samples were taken. Serum cathepsin D was measured using an abcam ELISA kit. RESULTS There were no significant differences between treatment and control groups in regard to weight, BMI, waist circumference and serum cathepsin D levels before and after the intervention. Also, there were no significant differences between pre and post-trial values of serum cathepsin D. CONCLUSION The results shows curcumin has not a significant effect on cathepsin D level in patients with MetS.